<DOC>
	<DOCNO>NCT01686451</DOCNO>
	<brief_summary>Both XueZhiKang Statins cholesterol-lowering medication often prescribed individual high cholesterol risk cardiovascular disease ( CVD ) . Several study , include one randomize , double-blind , placebo-controlled clinical trial , suggest use statins frequently associate fatigue . And XueZhiKang may . The purpose study compare effect two medication fatigue person moderate low CVD risk base risk estimation system ESC ( European Society Cardiology ) /ESA ( European Atherosclerosis Society ) guideline ( 2011 ) management dyslipidemias .</brief_summary>
	<brief_title>The Effect XueZhiKang Fatigue：Comparing With Simvastatin</brief_title>
	<detailed_description>Individuals risk cardiovascular disease ( CVD ) often prescribed statin , medication reduce amount cholesterol blood . By lower cholesterol level , individual low incidence coronary artery disease , ischemic stroke , peripheral arterial disease . While statin effective lower cholesterol level , effect fatigue obvious suggest several study , include one randomize , double-blind , placebo-controlled clinical trial . And XueZhiKang may . The purpose study compare effect two medication fatigue person moderate low CVD risk base risk estimation system ESC ( European Society Cardiology ) /ESA ( European Atherosclerosis Society ) guideline ( 2011 ) management dyslipidemias . This study enroll individual currently take cholesterol-lowering medication . Participants randomly assign receive 600mg XueZhiKang twice day , 20mg simvastatin daily 4 week . Study visit occur baseline Week 4 . Blood collect laboratory testing , standardized psychological questionnaire assess fatigue score physical activity level baseline week 4 . Pill count use assess adherence XueZhiKang simvastatin treatment week 4 . At week 4 , medication side effect monitor test alanine aminotransferase ( ALT ) , aspartate aminotransaminase ( AST ) creatine phosphate kinase ( CPK ) perform . At week 4 , medication efficacy assess test low-density lipoprotein cholesterol ( LDL-C ) perform .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . LDL cholesterol level 115190 mg/dL ; 2 . Able fast prior blood draw ; 3 . Able comfortably read write Chinese ; 4 . Able willing refrain donate whole blood study participation ; 5 . Willing abstain consume large amount grapefruit juice . 1 . Current use lipidlowering medication ; 2 . Documented cardiovascular disease ( CVD ) invasive noninvasive testing ( coronary angiography , nuclear imaging , stress echocardiography , carotid plaque ultrasound ) , previous myocardial infarction ( MI ) , acute coronary syndrome ( ACS ) , coronary revascularization [ percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) ] arterial revascularization procedure , ischaemic stroke , peripheral arterial disease ( PAD ) ; 3 . Patients type 2 diabetes , patient type 1 diabetes target organ damage ( microalbuminuria ) ; 4 . Patients moderate severe chronic kidney disease [ glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73㎡ ] ; 5 . Markedly elevate single risk factor familial dyslipidaemias severe hypertension ; 6 . A calculated SCORE ≥5 % 10 year risk fatal CVD ; 7 . Cancer ; 8 . HIV infect ; 9 . Medical psychiatric condition prevents full study participation followup ( e.g. , active psychosis ) ; 10 . Active liver disease unexplained persistent elevate transaminase levels； 11 . Major surgery hospitalization 3 month prior study entry ; 12 . Current use cyclosporin , erythromycin , clarithromycin , nefazodone , `` azole '' antifungal , include fluconazole , itraconazole , ketoconazole , mibefradil , protease inhibitor ; 13 . Female childbearing potential ; 14 . Current participation another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>